Data from a Phase II trial of ARN-509 (apalutamide) and more

A report posted on line in European Urology has provided us with important clinical data related to the potential of this investigational drug in the treatment of advanced prostate cancer. … READ MORE …

A look back at PIVOT … with additional data for context

Five years ago now, in May 2011, Wilt first presented the results of the PIVOT trial at the annual meeting of the American Urological Association in Washington, DC. A bit over a year later, the final results were published in the New England Journal of Medicine. … READ MORE …

International prostate cancer registry initiated in Australasia

According to a newly published article in BJU International, a new prostate cancer registry (Prostate Cancer Outcomes Registry — Australia and New Zealand or PCOR-ANZ) has been established to monitor outcomes of prostate cancer treatment and care “in a cost-effective manner”. … READ MORE …

How long is long enough? Length of follow-up on clinical trials for primary treatments

Many of us are faced with the difficulty of choosing a primary therapy based on data from clinical trials with follow-up shorter than our life expectancy. How can we know what to expect in 20 or 30 years? … READ MORE …

Targeting treatments for extraprostatic and oligometastatic prostate cancer with curative intent

The moderator of a well-known, prostate cancer-specific Internet forum recently wrote to us, stating,

There has been some assumption on the part of users of internet patient forums that the [newer and] more sensitive scans can be useful to detect major tumors that can be removed laparoscopically or treated with radiation, and that this would be beneficial.

… READ MORE …

New data from Johns Hopkins on outcomes after active surveillance

A new article from the group at Johns Hopkins has now confirmed that rates of prostate cancer-specific mortality and progression to metastatic disease are extremely low at 15 years of follow-up in their 18-year-long active surveillance cohort. … READ MORE …

Expectations and realities: are we really helping couples to cope post-treatment?

A recent review in the journal Translational Andrology and Urology, which is reprinted on line on the Medscape Oncology web site, addresses the issue of “Couples-based interventions following prostate cancer treatment.” … READ MORE …

Important new standards for data collection in studies of advanced prostate cancer

Recently we noted that Morgans et al. had published information about a proposed, standardized set of patient-centered outcomes data for advanced prostate cancer that would facilitate cross-comparison of data from the many trials that take now place in the management of TxNxM+ prostate cancer. … READ MORE …

Taking abiraterone acetate with and without food: some new data

A new paper in the journal Prostate Cancer and Prostatic Diseases suggests that, at least for some men, disease progression while on abiraterone acetate may be (temporarily) reversible when they take the drug with food as opposed to without food (the latter being the standard recommendation). … READ MORE …

Early data from an Australian registry of HIFU-treated patients

We should preface the following commentary by stating that there is no doubt that it takes time to learn to use high-intensity focused ultrasound (HIFU) really well as a form of first-line treatment for localized prostate cancer. This is hardly surprising. … READ MORE …

Active surveillance is absolutely NOT appropriate for all men with intermediate-risk prostate cancer

A paper to be presented this Thursday at the upcoming Genitourinary Cancers Symposium in  Orlando, Florida, will clearly confirm the above heading, which should come as no surprise to anyone. The issue has always been whether there is a subset of men with (“favorable”) intermediate-risk disease who are potentially appropriate candidates. … READ MORE …

When should therapeutic intervention take place for men on active surveillance?

The fact of the matter is that, as yet, we don’t have a good answer for this question, and it may be many years before we do. The reasons for this are numerous, but we are beginning to get some of the information we need to clarify the situation. … READ MORE …

Focal cryotherapy in the treatment of localized prostate cancer

A recent article in Expert Review of Anticancer Therapy has assessed the effectiveness and safety of focal cryotherapy in the first- and second-line treatment of localized prostate cancer. … READ MORE …

The value of the PCTRF comparative outcomes data

The “New” Prostate Cancer InfoLink wants to be clear for our readers that we are significantly less enthusiastic than others about some of the information being offered to patients, clinicians, and payers through the web site of an organization known as the Prostate Cancer Treatment Research Foundation (PCTRF). … READ MORE …

Other interesting active surveillance data from the AUA meeting in Orlando

In addition to the Sunnybrook data already reported today, three significant other studies presented at the AUA meeting have provided us with valuable information on the practical application of active surveillance. … READ MORE …